ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Sumitomo Dainippon Pharma Co., Ltd.

Business Summary

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue515,952M4,864.83M
Gross Profit378,307M3,567.00M
Operating income90,844M856.55M
Income before tax77,851M734.04M
Net income56,219M530.08M
EBITDA113,517M1,070.33M
Diluted EPS141.501.33
Dividends Per Share280.26
Total Assets1,308.12B11,838.25M
Total liabilities659,949M5,972.38M
Total equity580,570M5,254.02M
Operating cash flow135,601M1,278.56M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 408,357M 466,838M 459,267M 482,732M 515,952M
Gross Profit 307,911M 347,955M 337,856M 341,787M 378,307M
Operating income 60,974M 79,643M 57,207M 51,083M 90,844M
Income before tax 42,781M 84,866M 65,046M 83,947M 77,851M
Net income 31,316M 53,448M 48,627M 40,753M 56,219M
EBITDA 73,687M 92,530M 71,183M 68,448M 113,517M
Diluted EPS 78.82 134.53 122.39 102.57 141.50
Dividends Per Share 20 28 28 28 28
Total Assets 779,072M 809,684M 834,717M 1,252.87B 1,308.12B
Total liabilities 366,804M 356,961M 336,555M 620,773M 659,949M
Total equity 412,268M 452,723M 498,138M 529,485M 580,570M
Operating cash flow 19,143M 93,420M 48,711M 46,128M 135,601M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 3,771.04M 4,212.10M 4,141.47M 4,439.90M 4,864.83M
Gross Profit 2,843.45M 3,139.46M 3,046.63M 3,143.56M 3,567.00M
Operating income 563.07M 718.58M 515.86M 469.83M 856.55M
Income before tax 395.06M 765.71M 586.55M 772.09M 734.04M
Net income 289.19M 482.24M 438.49M 374.82M 530.08M
EBITDA 680.47M 834.86M 641.89M 629.54M 1,070.33M
Diluted EPS 0.72 1.21 1.10 0.94 1.33
Dividends Per Share 0.18 0.25 0.25 0.25 0.26
Total Assets 6,991.58M 7,613.38M 7,541.37M 11,605.55M 11,838.25M
Total liabilities 3,291.78M 3,356.47M 3,040.65M 5,750.29M 5,972.38M
Total equity 3,699.79M 4,256.91M 4,500.50M 4,904.68M 5,254.02M
Operating cash flow 176.77M 842.89M 439.25M 424.26M 1,278.56M

Valuation Measures

Mar 2021
PER13.61
ROA4.39%
ROE10.12%
Operating margin17.60%
Profit margin10.89%

Key executives

  • President & Representative Director: Hiroshi Nomura
  • GM-Production, Head-Research & Technology: Yoshiharu Ikeda
  • Executive Officer: Shigeyuki Nishinaka
  • Executive Officer: Antony Loebel
  • Representative Director: Toru Kimura

Shareholders

  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Inabata & Co., Ltd. (4.4%)
  • Nomura Asset Management Co., Ltd. (3.8%)
  • Nippon Life Insurance Co. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.8%)
  • Daiwa Asset Management Co. Ltd. (1.8%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Sumitomo Life Insurance Co. (1.4%)
  • MS&AD Insurance Group Holdings, Inc. (1.0%)
  • The Vanguard Group, Inc. (1.0%)

Contact Details

Related Companies

  • Spirovant Sciences Ltd.
  • DS Pharma Promo Co., Ltd.
  • Enzyvant Therapeutics Ltd.
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sumitovant Biophama, Inc.
  • Sumitovant Biopharma Ltd. (London)
  • Sumitovant Biopharma Ltd.
  • Sumitomo Dainippon Pharma Pension Fund
  • Urovant Sciences Ltd.
  • Myovant Sciences Ltd.
  • Sumitomo Dainippon Pharma America, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
  • Sunovion Pharmaceuticals Europe Ltd.
  • Sumitomo Dainippon Pharma Trust
  • DSP Gokyo Food & Chemical Co., Ltd.
  • DS Pharma Animal Health Co., Ltd.
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.

Competitors

  • VistaGen Therapeutics, Inc.
  • Cerevel Therapeutics Holdings Inc
  • Alkermes Plc
  • Vanda Pharmaceuticals Inc.
  • Intra-Cellular Therapies, Inc.
  • Sio Gene Therapies Inc
  • ACADIA Pharmaceuticals Inc.
  • Karuna Therapeutics, Inc.
  • Innoviva, Inc.
  • Acorda Therapeutics, Inc.
  • Impel NeuroPharma, Inc.
  • Adamas Pharmaceuticals, Inc.
  • Verona Pharma plc Sponsored ADR
  • Voyager Therapeutics, Inc.
  • Gossamer Bio, Inc.
  • Qurient Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Aravive, Inc.
  • BioLineRX Ltd.
  • Cyclacel Pharmaceuticals, Inc.
  • Kronos Bio Inc
  • Marinus Pharmaceuticals Inc
  • OptiNose, Inc.
  • SCYNEXIS, Inc.
  • SELLAS Life Sciences Group, Inc.
  • Silverback Therapeutics, Inc.
  • Terns Pharmaceuticals, Inc.
  • United Therapeutics Corporation
  • Vincerx, Inc
Last Updated on 18 Jun, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more